Core Viewpoint - The article highlights the strategic developments of Tuo Yun Biotechnology (透云生物), including significant stock movements and new business partnerships aimed at expanding its market presence in the algae product sector [1]. Group 1: Stock and Shareholder Information - On January 15, Tuo Yun Biotechnology's shareholders deposited stocks into Mingji Securities, with a total market value of HKD 36.5841 million, representing 5.85% of the company [1]. Group 2: Strategic Partnerships - Tuo Yun's wholly-owned subsidiary, Shanxi Tuo Yun, signed a strategic cooperation agreement on October 23 with Shenzhen Building Supply Chain Technology, Henan Guozi Marketing Management, and Beijing He Wan Jia Biotechnology, committing to procure no less than RMB 1 billion worth of Rhine algae and related products from 2026 to 2028 [1]. Group 3: Product Development and Market Expansion - In November 2024, Tuo Yun's Rhine algae received new usage approval from the National Health Commission, allowing the company to expand its applications and enter markets for artificial fish, shrimp, and plant-based milk [1].
透云生物股东将股票存入明玑证券 存仓市值3658.41万港元